Journal
/
/
Assays for Validating Histone Acetyltransferase Inhibitors
JoVE Journal
Cancer Research
A subscription to JoVE is required to view this content.  Sign in or start your free trial.
JoVE Journal Cancer Research
Assays for Validating Histone Acetyltransferase Inhibitors
DOI:

09:11 min

August 06, 2020

,

Chapters

  • 00:04Introduction
  • 00:39In Vitro HAT Assay
  • 01:37ChHAI Assay
  • 03:11Chromatin Immunoprecipitation (ChIP)
  • 05:48Results: Inhibitors of Histone Acetyltransferases
  • 08:19Conclusion

Summary

Automatic Translation

Inhibitors of histone acetyltransferases (HATs, also known as lysine acetyltransferases), such as CBP/p300, are potential therapeutics for treating cancer. However, rigorous methods for validating these inhibitors are needed. Three in vitro methods for validation include HAT assays with recombinant acetyltransferases, immunoblotting for histone acetylation in cell culture, and ChIP-qPCR.

Related Videos

Read Article